Lygos Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
60
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
25
Lygos General Information
Description
Operator of a sustainable specialty chemical company intended to replace persistent and sometimes toxic chemicals with products that are better, cleaner, and cost-effective. The company uses a multi-disciplined, vertically integrated platform that leverages partnerships across the value chain, enabling clients to develop and deliver products that are high-performing and sustainable.
Contact Information
Website
www.lygos.comCorporate Office
- 25821 Industrial Boulevard
- Suite 300
- Hayward, CA 94545
- United States
Corporate Office
- 25821 Industrial Boulevard
- Suite 300
- Hayward, CA 94545
- United States
Lygos Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 25. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 24. Later Stage VC | 01-Sep-2025 | Completed | Generating Revenue | |||
| 23. Accelerator/Incubator | 01-Jan-2024 | Completed | Generating Revenue | |||
| 22. Later Stage VC | 27-Oct-2022 | Completed | Generating Revenue | |||
| 21. Merger/Acquisition | 18-Apr-2022 | Cancelled | Generating Revenue | |||
| 20. Debt - PPP | 13-Apr-2020 | Completed | Generating Revenue | |||
| 19. Grant | 03-Jun-2019 | Completed | Generating Revenue | |||
| 18. Grant | 11-Mar-2019 | Completed | Generating Revenue | |||
| 17. Later Stage VC (Series B2) | 23-Jan-2019 | $15M | $49.7M | Completed | Generating Revenue | |
| 16. Grant | 31-Dec-2018 | $800K | $34.7M | Completed | Generating Revenue |
Lygos Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | ||||||||
| Series B | ||||||||
| Series A-6 | ||||||||
| Series A-5 | ||||||||
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 13,404,958 | $0.001000 | $0.73 | $0.73 | 1x | $0.73 | 15.11% | |
| Series A-1 | 6,648,543 | $0.001000 | 8% | $0.18 | $0.18 | 1x | $0.18 | 7.5% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Lygos Comparisons
Industry
Financing
Details
Lygos Competitors (13)
One of Lygos’s 13 competitors is Manus, a Venture Capital-Backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Manus | Venture Capital-Backed | Waltham, MA | ||||
| Amyris (Biotechnology) | Private Equity-Backed | Emeryville, CA | ||||
| Biocatalysts | Corporate Backed or Acquired | Cardiff, United Kingdom | ||||
| Mane | Corporation | Le Bar-sur-Loup, France | ||||
| Virent | Formerly VC-backed | Madison, WI |
Lygos Patents
Lygos Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025101434-A1 | Crosslinked superabsorbent polyaspartic acid or a salt thereof | Inactive | 10-Nov-2023 | ||
| WO-2024233705-A2 | Recombinant host cell for producing aspartate | Inactive | 08-May-2023 | ||
| WO-2024233705-A3 | Recombinant host cell for producing aspartate | Inactive | 08-May-2023 | ||
| WO-2024054828-A2 | Recombinant host cells for the production of malonate | Inactive | 06-Sep-2022 | ||
| WO-2024054828-A3 | Recombinant host cells for the production of malonate | Inactive | 06-Sep-2022 | C12N9/16 |
Lygos Signals
Lygos Investors (25)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Four Cities Capital | Venture Capital | Minority | ||
| Change Chemistry | Accelerator/Incubator | |||
| Flexible Solutions International | Corporation | Minority | ||
| Angel (individual) | Minority | |||
| LG Technology Ventures | Corporate Venture Capital | Minority |
Lygos Acquisitions (1)
Lygos’s most recent deal was a Merger/Acquisition with Librede for . The deal was made on 15-Jan-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Librede | 15-Jan-2020 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Lygos FAQs
-
When was Lygos founded?
Lygos was founded in 2011.
-
Where is Lygos headquartered?
Lygos is headquartered in Hayward, CA.
-
What is the size of Lygos?
Lygos has 60 total employees.
-
What industry is Lygos in?
Lygos’s primary industry is Specialty Chemicals.
-
Is Lygos a private or public company?
Lygos is a Private company.
-
What is Lygos’s current revenue?
The current revenue for Lygos is .
-
How much funding has Lygos raised over time?
Lygos has raised $210M.
-
Who are Lygos’s investors?
Four Cities Capital, Change Chemistry, Flexible Solutions International, , and LG Technology Ventures are 5 of 25 investors who have invested in Lygos.
-
Who are Lygos’s competitors?
Manus, Amyris (Biotechnology), Biocatalysts, Mane, and Virent are some of the 13 competitors of Lygos.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process